The economic impact of OFF periods in Parkinson disease
- PMID: 33058689
- DOI: 10.37765/ajmc.2020.88518
The economic impact of OFF periods in Parkinson disease
Abstract
Parkinson disease affects nearly 1 million people in the United States, and the prevalence is expected to increase to at least 1.2 million people by 2030. Parkinson disease is a chronic, incurable disease. Most treatments focus on controlling motor symptoms; however, as the disease progresses, periods of reduced therapeutic benefit, or OFF periods, become more frequent and increasingly troublesome. OFF periods contribute to the already substantial economic burden of Parkinson disease. People with Parkinson disease who experience OFF periods and their caregivers have reported more work days with low productivity and more missed work days compared with those who do not experience OFF periods. More caregivers of people with Parkinson disease who experience OFF episodes reported that due to the disease, they had reduced or changed working hours, lost opportunities, or had reduced work productivity, and these caregivers reported an average of more than twice the amount of employment income lost compared with caregivers of people with Parkinson disease who do not experience OFF periods.
Similar articles
-
Exploring the clinical burden of OFF periods in Parkinson disease.Am J Manag Care. 2020 Oct;26(12 Suppl):S255-S264. doi: 10.37765/ajmc.2020.88517. Am J Manag Care. 2020. PMID: 33058688
-
United States Patients' Perspective of Living With Migraine: Country-Specific Results From the Global "My Migraine Voice" Survey.Headache. 2020 Jul;60(7):1351-1364. doi: 10.1111/head.13829. Epub 2020 May 5. Headache. 2020. PMID: 32369201 Free PMC article.
-
Experience and Impact of OFF Periods in Parkinson's Disease: A Survey of Physicians, Patients, and Carepartners.J Parkinsons Dis. 2020;10(1):315-324. doi: 10.3233/JPD-191785. J Parkinsons Dis. 2020. PMID: 31815702
-
On demand therapy for Parkinson's disease patients: Opportunities and choices.Postgrad Med. 2021 Sep;133(7):721-727. doi: 10.1080/00325481.2021.1936087. Epub 2021 Jun 30. Postgrad Med. 2021. PMID: 34082655 Review.
-
Caregiver Burden in Parkinson Disease: A Critical Review of Recent Literature.J Geriatr Psychiatry Neurol. 2017 Sep;30(5):235-252. doi: 10.1177/0891988717720302. Epub 2017 Jul 26. J Geriatr Psychiatry Neurol. 2017. PMID: 28743212 Review.
Cited by
-
Cost-Effectiveness of Apomorphine Sublingual Film as an "On-Demand" Treatment for "OFF" Episodes in Patients with Parkinson's Disease.J Health Econ Outcomes Res. 2021 Nov 17;8(2):82-92. doi: 10.36469/jheor.2021.29488. eCollection 2021. J Health Econ Outcomes Res. 2021. PMID: 35178465 Free PMC article.
-
Evaluation of the efficacy and cost-effectiveness of safinamide versus rasagiline: a systematic review.J Comp Eff Res. 2025 Sep;14(9):e250031. doi: 10.57264/cer-2025-0031. Epub 2025 Aug 14. J Comp Eff Res. 2025. PMID: 40810286 Free PMC article. Review.
-
Caregiver Burden in Parkinson Disease: A Scoping Review of the Literature from 2017-2022.J Geriatr Psychiatry Neurol. 2024 Mar;37(2):96-113. doi: 10.1177/08919887231195219. Epub 2023 Aug 8. J Geriatr Psychiatry Neurol. 2024. PMID: 37551798 Free PMC article.
-
The Clinical Development of Levodopa Inhalation Powder.Clin Neuropharmacol. 2023 Mar-Apr 01;46(2):66-78. doi: 10.1097/WNF.0000000000000540. Epub 2023 Jan 29. Clin Neuropharmacol. 2023. PMID: 36715241 Free PMC article.
-
Effective Management of "OFF" Episodes in Parkinson's Disease: Emerging Treatment Strategies and Unmet Clinical Needs.Neuropsychiatr Dis Treat. 2023 Jan 25;19:247-266. doi: 10.2147/NDT.S273121. eCollection 2023. Neuropsychiatr Dis Treat. 2023. PMID: 36721795 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical